- Home
- TWIN vs ACRS Comparison
TWIN vs ACRS Comparison
Compare TWIN & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWIN
- ACRS
- Stock Information
- Founded
- TWIN 1918
- ACRS 2012
- Country
- TWIN United States
- ACRS United States
- Employees
- TWIN N/A
- ACRS N/A
- Industry
- TWIN Industrial Machinery/Components
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- TWIN Industrials
- ACRS Health Care
- Exchange
- TWIN Nasdaq
- ACRS Nasdaq
- Market Cap
- TWIN 186.2M
- ACRS 198.2M
- IPO Year
- TWIN N/A
- ACRS 2015
- Fundamental
- Price
- TWIN $14.99
- ACRS $1.79
- Analyst Decision
- TWIN Strong Buy
- ACRS Strong Buy
- Analyst Count
- TWIN 1
- ACRS 9
- Target Price
- TWIN $12.00
- ACRS $9.25
- AVG Volume (30 Days)
- TWIN 34.7K
- ACRS 931.5K
- Earning Date
- TWIN 11-05-2025
- ACRS 11-05-2025
- Dividend Yield
- TWIN 1.12%
- ACRS N/A
- EPS Growth
- TWIN N/A
- ACRS N/A
- EPS
- TWIN N/A
- ACRS N/A
- Revenue
- TWIN $340,738,000.00
- ACRS $16,789,000.00
- Revenue This Year
- TWIN $10.79
- ACRS N/A
- Revenue Next Year
- TWIN $8.43
- ACRS $7.02
- P/E Ratio
- TWIN N/A
- ACRS N/A
- Revenue Growth
- TWIN 15.46
- ACRS N/A
- 52 Week Low
- TWIN $6.16
- ACRS $1.05
- 52 Week High
- TWIN $15.00
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- TWIN 66.28
- ACRS 41.98
- Support Level
- TWIN $14.11
- ACRS $1.86
- Resistance Level
- TWIN $15.00
- ACRS $1.97
- Average True Range (ATR)
- TWIN 0.67
- ACRS 0.09
- MACD
- TWIN -0.03
- ACRS -0.01
- Stochastic Oscillator
- TWIN 97.05
- ACRS 14.79
About TWIN Twin Disc Incorporated
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.